File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: SIRT1 in metabolic syndrome: Where to target matters

TitleSIRT1 in metabolic syndrome: Where to target matters
Authors
KeywordsAging
Cardiovascular Diseases
Metabolic Disorders
Silent Information Regulator
Sirtuin
Issue Date2012
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmthera
Citation
Pharmacology And Therapeutics, 2012, v. 136 n. 3, p. 305-318 How to Cite?
AbstractSirtuin 1 (SIRT1), the mammalian ortholog of yeast Sir2p, is a highly conserved NAD +-dependent protein deacetylase that has emerged as a key cardiometabolic regulator. During the past decade, Sir2p has been the focus of intense investigations and discussion because it regulates longevity in yeast, worms and flies. Although the extrapolation of data obtained from yeast Sir2p to mammalian SIRT1 cannot be automatic, animal studies provide convincing evidence that SIRT1 is a potent protector against aging-associated pathologies, in particular metabolic disorders and cardiovascular diseases. Indeed, many exciting connections exist between the protein deacetylation function of SIRT1 and its role in fundamental biological responses to various nutritional and environmental signals. As a result, pharmaceutical and nutriceutical interventions targeting SIRT1 are promising strategies to combat aging-associated diseases. The present review summarizes the recent progress in SIRT1 research with a particular focus on the specificities of this protein in individual tissues as they relate to cardiometabolic control. © 2012 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/171452
ISSN
2015 Impact Factor: 11.0
2015 SCImago Journal Rankings: 4.090
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Yen_US
dc.contributor.authorXu, Cen_US
dc.contributor.authorLiang, Yen_US
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:14:21Z-
dc.date.available2012-10-30T06:14:21Z-
dc.date.issued2012en_US
dc.identifier.citationPharmacology And Therapeutics, 2012, v. 136 n. 3, p. 305-318en_US
dc.identifier.issn0163-7258en_US
dc.identifier.urihttp://hdl.handle.net/10722/171452-
dc.description.abstractSirtuin 1 (SIRT1), the mammalian ortholog of yeast Sir2p, is a highly conserved NAD +-dependent protein deacetylase that has emerged as a key cardiometabolic regulator. During the past decade, Sir2p has been the focus of intense investigations and discussion because it regulates longevity in yeast, worms and flies. Although the extrapolation of data obtained from yeast Sir2p to mammalian SIRT1 cannot be automatic, animal studies provide convincing evidence that SIRT1 is a potent protector against aging-associated pathologies, in particular metabolic disorders and cardiovascular diseases. Indeed, many exciting connections exist between the protein deacetylation function of SIRT1 and its role in fundamental biological responses to various nutritional and environmental signals. As a result, pharmaceutical and nutriceutical interventions targeting SIRT1 are promising strategies to combat aging-associated diseases. The present review summarizes the recent progress in SIRT1 research with a particular focus on the specificities of this protein in individual tissues as they relate to cardiometabolic control. © 2012 Elsevier Inc. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmtheraen_US
dc.relation.ispartofPharmacology and Therapeuticsen_US
dc.subjectAgingen_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectMetabolic Disordersen_US
dc.subjectSilent Information Regulatoren_US
dc.subjectSirtuinen_US
dc.titleSIRT1 in metabolic syndrome: Where to target mattersen_US
dc.typeArticleen_US
dc.identifier.emailWang, Y:yuwanghk@hku.hken_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityWang, Y=rp00239en_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.pharmthera.2012.08.009en_US
dc.identifier.pmid22939883-
dc.identifier.scopuseid_2-s2.0-84867880208en_US
dc.identifier.hkuros219895-
dc.identifier.isiWOS:000311022900004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWang, Y=34973733700en_US
dc.identifier.scopusauthoridXu, C=55245075900en_US
dc.identifier.scopusauthoridLiang, Y=55273172800en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.citeulike11777194-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats